Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 10/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.51 |
| ▸ | AURKA | O14965 | 4/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 6/20 | 0.49 |
| ▸ | CCND2 | P30279 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284543 | 0.91 | STAT6 (0.51) | CDK4FGFR4AURKACDK1JAK2 | |
| SCHEMBL1285380 | 0.91 | JAK3 (0.47) | CDK4FGFR4AURKACDK1INSR | |
| SCHEMBL1285114 | 0.88 | JAK3 (0.45) | CDK4FGFR4AURKACDK1INSR | |
| SCHEMBL1284832 | 0.88 | JAK3 (0.38) | CDK4FGFR4AURKACDK1INSR | |
| SCHEMBL1285557 | 0.87 | STAT6 (0.48) | FLT4KDRJAK3JAK2BRD4 | |
| SCHEMBL1284495 | 0.87 | JAK2 (0.38) | CDK4FGFR4AURKACDK1INSR | |
| SCHEMBL1285257 | 0.87 | PTK2 (0.43) | SRCJAK3CSF1R | |
| SCHEMBL1284917 | 0.85 | MAPK8 (0.47) | CDK4CDK1SRCCDK7JAK3 | |
| SCHEMBL1284416 | 0.84 | JAK3 (0.49) | FLT4KDRCDK7JAK3JAK2 | |
| SCHEMBL1284506 | 0.84 | CAMK2D (0.43) | CDK4AURKACDK1SRCJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | CDK4 85/4885FGFR4 755/4885AURKA 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.